Effects of intracoronary antithrombotics on ventricular function: A comparison of tenecteplase versus abciximab during primary percutaneous intervention in myocardial infarction

Ficheros
Estadísticas
Métricas y Citas
Metadatos
Mostrar el registro completo del ítemFecha
2021-01Departamento/s
MedicinaFuente
Cardiology Journal 2021, Vol. 28, No. 1, 176–178Resumen
Adjunctive medical therapy during primary
percutaneous coronary intervention (PPCI) is
based on anticoagulation and antiplatelet drugs. Additionally,
the glycoprotein IIb/IIIa inhibitor (GPI)
abciximab has been shown to reduce infarct size in
some clinical trials [1]. However, the role of intracoronary
fibrinolysis has not been well established
during PPCI. We sought to explore the hypothesis
that a locally administered fibrinolytic could be
more effective in dissolving coronary thrombus
at the macro and microvasculature than adding
a third antiplatelet drug in patients already receiving
double antiplatelet therapy, and therefore improve
myocardial perfusion and left ventricular function.
Colecciones
- Artículos Científicos [12014]
- Articulos Científicos Medicina [306]






